ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,615.35
0.55%
US Tech 100
19,804.00
0.64%
Dow Jones
40,000.90
0.62%
Brent Oil
84.57
0.00%
Bitcoin
58,659.00
1.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Boundless Bio Inc (BOLD) Quote

Boundless Bio Inc

Boundless Bio Inc (BOLD)

21Shares AG
21Shares AG
4.08
-0.12
(-2.86%)
Closed July 13 4:00PM
Delayed by 15 minutes
4.08
0.00
(0.00%)
After Hours: 5:16PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.08
Bid
3.58
Ask
4.63
Volume
39,760
3.94 Day's Range 4.29
3.75 52 Week Range 15.20
Market Cap
93.469M
Previous Close
4.20
Open
4.29
Last Trade
461
@
4.08
(priorref)
Last Trade Time
Financial Volume
$ 162,634
VWAP
4.0904
Average Volume (3m)
108,354
Shares Outstanding
22,254,537
Dividend Yield
-
PE Ratio
-1.84
Earnings Per Share (EPS)
-2.22
Revenue
-
Net Profit
-49.43M

About Boundless Bio Inc

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.boundlessbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was $4.20. Over the last year, Boundless Bio shares have traded in a share price range of $ 3.75 to $ 15.20.

Boundless Bio currently has 22,254,537 shares outstanding. The market capitalization of Boundless Bio is $93.47 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.84.

BOLD Latest News

More News

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

June 05 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 13 2024
Edgar (US Regulatory)

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2...

May 13 2024
Business Wire

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

May 06 2024
Business Wire

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...

April 11 2024
Business Wire

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...

April 08 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.16-3.773584905664.244.52843.94480394.27418339CS
4-3.18-43.80165289267.267.573.751404025.14269798CS
12-7.42-64.521739130411.512.64843.751083548.11406636CS
26-10.17-71.368421052614.2515.23.7514241010.03412985CS
52-10.17-71.368421052614.2515.23.7514241010.03412985CS
156-10.17-71.368421052614.2515.23.7514241010.03412985CS
260-30.09-88.059701492534.17603.7558495845.94727817CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.69M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

Discussion

View Full Feed
karlacorn3 karlacorn3 4 minutes ago
... I'm sure many are wondering regarding the 12th. Perhaps Laxmi will deliver great news.
K
ITUP
GOSPEL-BELIEVER-35 GOSPEL-BELIEVER-35 4 minutes ago
$FUNR is not at all starting from "Scratch" and oneday you need to please realize Sir this below.
The CEO & Board Director of FUNR is sitting on a very valuable Public Company that is Regulatory compliant, Trading Pink Current, Transfer agent is up to date, All Filings are current, Service pr
FUNR
LTListener LTListener 5 minutes ago
This company has multiple drug development programs working with the DOD and NIH with very prominent professionals involved. I dont quite understand how on earth this was allowed to get to this point with filings especially since there were plenty of options. Only thing one can imagine is they hav
RSPI
ExtremelyBullishZig ExtremelyBullishZig 5 minutes ago
There is plenty of evidence...one big one is not providing the data. And changing the goal posts. Oh and the market agrees...hence the price.
AVXL
ddls ddls 6 minutes ago
They're a little bitter because sales never made 5 to 10 million in 2017, as per the Commander and Chief at that time.

They need to STOP PRETENDING.
BIEL
mzasif mzasif 6 minutes ago
My point was to say there will be most likely a news per his recent tweet. I don't follow him like I used to. I have stopped communicating with him about a month ago. I am just taking a chance of the very low pps and what the charts are telling me. Reversal is imminent...a good news will give it an
BLEG
judypudy judypudy 6 minutes ago
Just checked and my Schwab account and like you it shows Cerebain. But my Think or Swim doesn't show Cerebain anymore. It shows 15672M106 again.
CBBT
ExtremelyBullishZig ExtremelyBullishZig 7 minutes ago
You should care...or in denial and an idiot.
AVXL
hap0206 hap0206 7 minutes ago
All the talk about CC debt -- so how did four years of Trump economy stack up against the Biden economy -- read it and weep dems
========
In Millions-- Revolving non-secured debt -- mainly credit card debt

jan 2017 $963,173.70

jan 2021 -- $971,735.59
hedge_fun hedge_fun 7 minutes ago
Looking forward to Plan B, C, D……

and E.

#deletedarea
#itsnotundertheteredocrust
#whatashock
SFRX
Money4Nothing-M4N Money4Nothing-M4N 7 minutes ago
You really need to do homework on what you own.

Yes. Certain. Do you not read news? Not aware of all the A-listers that have done exactly what I said?

"I guarantee you have no idea what you are talking about."

You poor thing. Always getting picked on.
KBLB
Lime Time Lime Time 8 minutes ago
I don't care what you buy. I don't buy tickers like this. This is lower than pig feces. Management should be arrested, instead, they are cruising the Caribbean in their 25b dollar yatchs sipping on fine wine and accepting revocation so that this will finally be put to bed, forever.
RNVA
tmcfo tmcfo 9 minutes ago
That’s great! Here are the restaurants: Aka Sushi House and Tiger Den.
When will you be in houston?
MVNT
buylow2 buylow2 10 minutes ago
Hey Chaz, do you know if we have any patents that are still valid?
HDVY
Fai 2 Fai 2 10 minutes ago
Yes yes and yes loll I remember all those lies told 100s of times about DBMM as if it were facts. Go DBMM


"The worst news is behind us......

Mostly people manipulate stocks with below lines....

Bankruptcy soon......

Revocation s
DBMM
jetow jetow 10 minutes ago
It really took balls to tell Money For Nothing the following "I guarantee you have no idea what you are talking about."

My response..... and you think we believe you do???
KBLB
LuckyLovie LuckyLovie 13 minutes ago
Let's see fish/ pbilly...u list allot on srnw 60 cents to 12 cents...u got killed on envy and gvsi....then you took out a loan and bought ronn that's at 0027...then Chinese food pennie 0.018 to 0.0057....how can you even exsist in life with all LOSING PENNIE PLAYS...

GEEZ if you went
GVSI
shermann7 shermann7 14 minutes ago
Why Inflation Will Return To 9%; 85% Chance Of Fed Cut By September | Brett Heath - David Lin - VIDEO

https://www.youtube.com/watch?v=srT36HXSw0I

Shermann
DimesForShares DimesForShares 14 minutes ago
#dumptoddlers
KBLB
awesomed007 awesomed007 14 minutes ago
You do you, and I will keep adding spzi shares, all good. I love my spzi position. It costs me nothing to buy on Fidelity and my holding is up a couple hundred percent. Fed is going start cutting interest rates this September and otc micro cap stocks are going to run, and run hard, historically that
SPZI
LetGoodTimesRoll LetGoodTimesRoll 16 minutes ago
Woooooooh $RNVA!!! $$$$$$$
RNVA
DR_rugby DR_rugby 16 minutes ago
Breaking news RK announcement not

https://m.youtube.com/watch?v=A_rpyhMRVJc

Imagine you had thousands of chances to fund your life opportunities and you get ahead

Imagine general kitty announces

Enemy looses will to fight and looses powe
GME
DimesForShares DimesForShares 16 minutes ago
The whole ‘Dump Kings’ movement is based on an absurd fantasy.

First, we both understand KBLB isn’t restricted to selling all of their silk to Kings. The two companies negotiated a contract where a specific quantity of silk would be provided each year at a specific cost. Once KBLB e
KBLB

Your Recent History

NASDAQ
BOLD
Boundless Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved